These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16158403)

  • 1. Minmax designs for planning the second phase in a two-phase case-control study.
    Schill W; Wild P
    Stat Med; 2006 May; 25(10):1646-59. PubMed ID: 16158403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A planning tool for two-phase case-control studies.
    Schill W; Wild P; Pigeot I
    Comput Methods Programs Biomed; 2007 Nov; 88(2):175-81. PubMed ID: 17869374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Including sampling and phenotyping costs into the optimization of two stage designs for genomewide association studies.
    Müller HH; Pahl R; Schäfer H
    Genet Epidemiol; 2007 Dec; 31(8):844-52. PubMed ID: 17549751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simulation study of control sampling methods for nested case-control studies of genetic and molecular biomarkers and prostate cancer progression.
    Wang MH; Shugart YY; Cole SR; Platz EA
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):706-11. PubMed ID: 19258478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The analysis of case-control studies under validation subsampling.
    Schill W; Jöckel KH
    Eur J Clin Nutr; 1993 Oct; 47 Suppl 2():S34-41. PubMed ID: 8262016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update of potency factors for asbestos-related lung cancer and mesothelioma.
    Berman DW; Crump KS
    Crit Rev Toxicol; 2008; 38 Suppl 1():1-47. PubMed ID: 18671157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust and efficient design of experiments for the Monod model.
    Dette H; Melas VB; Pepelyshev A; Strigul N
    J Theor Biol; 2005 Jun; 234(4):537-50. PubMed ID: 15808874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal adaptive design in clinical drug development: a simulation example.
    Maloney A; Karlsson MO; Simonsson US
    J Clin Pharmacol; 2007 Oct; 47(10):1231-43. PubMed ID: 17906158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Logistic regression methods for retrospective case-control studies using complex sampling procedures.
    Fears TR; Brown CC
    Biometrics; 1986 Dec; 42(4):955-60. PubMed ID: 3814735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating interaction between genetic and environmental risk factors: efficiency of sampling designs within a cohort.
    Bureau A; Diallo MS; Ordovas JM; Cupples LA
    Epidemiology; 2008 Jan; 19(1):83-93. PubMed ID: 18091418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of matched case-control data with incomplete strata: applying longitudinal approaches.
    Lin IF; Lai MY; Chuang PH
    Epidemiology; 2007 Jul; 18(4):446-52. PubMed ID: 17525695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal sampling in retrospective logistic regression via two-stage method.
    Chien CY; Ivan Chang YC; Hsueh HM
    Biom J; 2011 Feb; 53(1):5-18. PubMed ID: 21259305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Balanced two-stage designs for phase II clinical trials.
    Ye F; Shyr Y
    Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of efficient designs for observational epidemiologic studies.
    Kalish LA; Begg CB
    Biometrics; 1987 Mar; 43(1):145-67. PubMed ID: 3567303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficiency of cohort sampling designs: some surprising results.
    Langholz B; Thomas DC
    Biometrics; 1991 Dec; 47(4):1563-71. PubMed ID: 1786329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis of asbestos-related cancer risk that addresses fiber size and mineral type.
    Berman DW; Crump KS
    Crit Rev Toxicol; 2008; 38 Suppl 1():49-73. PubMed ID: 18686078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective studies of diagnostic test accuracy when disease prevalence is low.
    Obuchowski NA; Zhou XH
    Biostatistics; 2002 Dec; 3(4):477-92. PubMed ID: 12933593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal robust two-stage designs for genome-wide association studies.
    Nguyen TT; Pahl R; Schäfer H
    Ann Hum Genet; 2009 Nov; 73(Pt 6):638-51. PubMed ID: 19839987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.